NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.

Don't have an account? Subscribe

HSE drugs group recommends intranasal naloxone be added to drugs scheme

By Mindo - 03rd Dec 2020

The HSE drugs group has recommended that intranasal naloxone be included under the community drugs schemes for GPs, the Medical Independent has learned. The HSE’s executive management team (EMT) is considering this recommendation.

At the HSE drugs group meeting in June, it was “unanimously recommended that intranasal naloxone should be included under the community drugs schemes for GPs designated as level one and level two opioid substitution treatment prescribers to be able to prescribe this medicine for storage and administration in the home in the event of the accidental overdose of opioids”.

According to meeting minutes, the group recognised that drug-related mortality rates in Ireland are among the highest in the EU and welcomed the expansion of naloxone services in that context.

“The group were assured that HSE addiction services were supportive of this product being available under the scheme. The overall drug budget impact presented was considered to be relatively modest.”

Intranasal naloxone is currently available through the HSE naloxone demonstration project. Up until the end of July, the HSE provided 1,601 packs of Prenoxad (injectable naloxone) and 1,700 packs of Nyxoid (intranasal naloxone).

Leave a Reply

Latest Issue
The Medical Independent 26th September 2023

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read